stockrowBristol Myers Squibb Company (BMY) vs Novartis AG (NVS)
- Bristol Myers Squibb Company BMY 62.46 −1.06%
- Novartis AG NVS 162.33 +0.25%
Bristol Myers Squibb Company and Novartis AG are both Drug Manufacturers General companies. Novartis AG is the larger, with a market value of $296.4B against $129.0B — 2.3× the size. Bristol Myers Squibb Company trades at the lower P/E: 14.0× against 30.9×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 4.16% against 1.76%. Bristol Myers Squibb Company has the higher net margin (18.5% vs 17.5%) and the higher return on invested capital (13.2% vs 12.1%). Both pay a dividend; Bristol Myers Squibb Company yields more (3.99% vs 2.93%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 16 and Novartis AG on 7.
Valuation
Profitability
| Metric | BMY | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.24% | 74.92% | 73.01% |
| Operating margin | 22.65% | 25.18% | 18.34% |
| Net margin | 18.47% | 17.49% | 7.31% |
| Free cash flow margin | 18.56% | 24.66% | 18.52% |
| Return on equity | 44.01% | 24.37% | 5.80% |
| Return on assets | 9.96% | 8.94% | 2.28% |
| Return on invested capital | 13.19% | 12.05% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack